S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

INTS Intesity Therapeutics Inc

2.20

-0.01 (-0.45%)

01 Feb 2025 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Intesity Therapeutics Charts.

Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Intesity Therapeutics Charts.

Intesity Therapeutics Inc News

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
Wednesday 29 January 2025 (5 days ago) • PR Newswire (US)

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Saturday 11 January 2025 (3 weeks ago) • PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Tuesday 31 December 2024 (1 month ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Saturday 21 December 2024 (1 month ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Saturday 14 December 2024 (2 months ago) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer
Friday 13 December 2024 (2 months ago) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Friday 22 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 22 November 2024 (2 months ago) • Edgar (US Regulatory)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Friday 22 November 2024 (2 months ago) • PR Newswire (US)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Thursday 21 November 2024 (2 months ago) • Edgar (US Regulatory)

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Tuesday 19 November 2024 (3 months ago) • PR Newswire (US)

Form 8-K - Current report
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

More Intesity Therapeutics Inc News Articles

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions